Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4477469 | 0.90 | PDE1C (0.47) | RAB9ANPC1KMT2AADORA3MAPT | |
| SCHEMBL4494571 | 0.89 | RAB9A (0.50) | RAB9ANPC1KMT2AADORA3MAPT | |
| SCHEMBL4490038 | 0.85 | NPC1 (0.49) | RAB9ANPC1KMT2AMAPTSTAT1 | |
| SCHEMBL4491743 | 0.84 | MEN1 (0.54) | ARRAB9AKMT2AADORA3MAPT | |
| SCHEMBL4485662 | 0.84 | GCGR (0.48) | RAB9ANPC1KMT2AMAPTSTAT1 | |
| SCHEMBL4492335 | 0.83 | RAB9A (0.43) | ARRAB9ANPC1KMT2AADORA3 | |
| SCHEMBL4494081 | 0.80 | RAB9A (0.47) | ARRAB9ANPC1KMT2AMAPT | |
| SCHEMBL4486128 | 0.79 | KMT2A (0.52) | RAB9ANPC1KMT2AADORA3MAPT | |
| SCHEMBL4492326 | 0.79 | RAB9A (0.51) | RAB9ANPC1KMT2AMAPTSTAT1 | |
| SCHEMBL4502843 | 0.79 | RAB9A (0.49) | RAB9ANPC1KMT2AMAPTSTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | claimed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | claimed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504429-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1651599-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20060189577-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2006-08-24 | — | — | US | disclosed |
| EP-1651599-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009957-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189577-A1 | Tyrosine kinase inhibitors | ABL1, RET, ERBB2 | AR 1244/4885RAB9A 2642/4885NPC1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.